NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

腎生物標記的全球市場

Renal Biomarker

出版商 Global Industry Analysts, Inc. 商品編碼 997548
出版日期 內容資訊 英文 236 Pages
商品交期: 最快1-2個工作天內
價格
腎生物標記的全球市場 Renal Biomarker
出版日期: 2021年04月01日內容資訊: 英文 236 Pages
簡介

全球腎生物標記的市場規模,預計在分析期間(2020年∼2027年)將以5.6%的年複合成長率增長,從2020年的11億美元,到2027年達到16億美元。

本報告所分析的市場區隔之一的功能性生物標記部門,在分析期間中預計將以6%的年複合成長率增長,達到9億2,340萬美元。

本報告提供全球腎生物標記市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Abbott Molecular, Inc.
  • Astute Medical, Inc.
  • Beckman Coulter, Inc.
  • BioPorto Diagnostics A/S
  • Randox Laboratories Ltd.
  • Thermo Fisher Scientific, Inc.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:44公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP14406

Abstract:

Global Renal Biomarker Market to Reach $1.6 Billion by 2027

Amid the COVID-19 crisis, the global market for Renal Biomarker estimated at US$1.1 Billion in the year 2020, is projected to reach a revised size of US$1.6 Billion by 2027, growing at a CAGR of 5.6% over the analysis period 2020-2027. Functional Biomarker, one of the segments analyzed in the report, is projected to record a 6% CAGR and reach US$923.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Up-Regulated Protein segment is readjusted to a revised 5.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $321.7 Million, While China is Forecast to Grow at 5.2% CAGR

The Renal Biomarker market in the U.S. is estimated at US$321.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$281 Million by the year 2027 trailing a CAGR of 5.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.4% and 4.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Other Biomarkers Segment to Record 4.9% CAGR

In the global Other Biomarkers segment, USA, Canada, Japan, China and Europe will drive the 4.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$91.2 Million in the year 2020 will reach a projected size of US$127.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$183.4 Million by the year 2027.

Select Competitors (Total 44 Featured) -

  • Abbott Molecular, Inc.
  • Astute Medical, Inc.
  • Beckman Coulter, Inc.
  • BioPorto Diagnostics A/S
  • Randox Laboratories Ltd.
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Renal Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Renal Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Renal Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Functional Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Functional Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Functional Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Up-Regulated Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Up-Regulated Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Up-Regulated Protein by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Other Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Enzyme Linked Immunosorbent Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Enzyme Linked Immunosorbent Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Enzyme Linked Immunosorbent Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Particle-Enhanced Turbidimetric Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Particle-Enhanced Turbidimetric Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Particle-Enhanced Turbidimetric Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Colorimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Colorimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Colorimetric Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Chemiluminescent Enzyme Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Chemiluminescent Enzyme Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Chemiluminescent Enzyme Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Liquid Chromatography-Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Liquid Chromatography-Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Liquid Chromatography-Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Diagnostic Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Outpatient Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Outpatient Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Outpatient Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 38: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 40: USA Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: USA Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: USA 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 43: USA Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: USA Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: USA 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2020 & 2027
    • TABLE 46: USA Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: USA Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: USA 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 49: Canada Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Canada Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Canada 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 52: Canada Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Canada Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Canada 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2020 & 2027
    • TABLE 55: Canada Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Canada Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Canada 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 58: Japan Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Japan Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Japan 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 61: Japan Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Japan Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: Japan 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2020 & 2027
    • TABLE 64: Japan Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Japan Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Japan 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 67: China Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: China Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: China 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 70: China Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: China Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: China 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2020 & 2027
    • TABLE 73: China Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: China Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: China 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 76: Europe Current & Future Analysis for Renal Biomarker by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 77: Europe Historic Review for Renal Biomarker by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Europe 15-Year Perspective for Renal Biomarker by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 79: Europe Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Europe Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Europe 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 82: Europe Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Europe Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Europe 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2020 & 2027
    • TABLE 85: Europe Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Europe Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Europe 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 88: France Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: France Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: France 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 91: France Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: France Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: France 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2020 & 2027
    • TABLE 94: France Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: France Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: France 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 97: Germany Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Germany Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Germany 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 100: Germany Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Germany Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Germany 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2020 & 2027
    • TABLE 103: Germany Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Germany Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: Germany 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 106: Italy Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Italy Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: Italy 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 109: Italy Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Italy Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: Italy 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2020 & 2027
    • TABLE 112: Italy Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Italy Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: Italy 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 115: UK Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: UK Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: UK 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 118: UK Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: UK Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: UK 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2020 & 2027
    • TABLE 121: UK Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: UK Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: UK 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 124: Rest of Europe Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Rest of Europe Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: Rest of Europe 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 127: Rest of Europe Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Rest of Europe Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Rest of Europe 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2020 & 2027
    • TABLE 130: Rest of Europe Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Rest of Europe Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Rest of Europe 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 133: Asia-Pacific Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Asia-Pacific Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Asia-Pacific 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 136: Asia-Pacific Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Asia-Pacific Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Asia-Pacific 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2020 & 2027
    • TABLE 139: Asia-Pacific Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Asia-Pacific Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: Asia-Pacific 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 142: Rest of World Current & Future Analysis for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Rest of World Historic Review for Renal Biomarker by Biomarker - Functional Biomarker, Up-Regulated Protein and Other Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: Rest of World 15-Year Perspective for Renal Biomarker by Biomarker - Percentage Breakdown of Value Sales for Functional Biomarker, Up-Regulated Protein and Other Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 145: Rest of World Current & Future Analysis for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Rest of World Historic Review for Renal Biomarker by Diagnostic Technique - Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: Rest of World 15-Year Perspective for Renal Biomarker by Diagnostic Technique - Percentage Breakdown of Value Sales for Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay and Liquid Chromatography-Mass Spectrometry for the Years 2012, 2020 & 2027
    • TABLE 148: Rest of World Current & Future Analysis for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Rest of World Historic Review for Renal Biomarker by End-Use - Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: Rest of World 15-Year Perspective for Renal Biomarker by End-Use - Percentage Breakdown of Value Sales for Diagnostic Labs, Outpatient Clinics, Research Centers and Hospitals for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 44